![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or “step down” to either fluticasone propionate (FP) 100mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 weeks. Overall asthma control significantly improved in the FSC group; whereas, “stepping down” to FP, SAL, or MON resulted in deterioration in asthma control, as determined by decreased measures of lung function and clinical features. This study provides support that treatment of both inflammation and smooth muscle dysfunction may be necessary to achieve and maintain asthma control in patients uncontrolled on ICS.
| Abbreviations | ||
| AM PEF | = | morning peak expiratory flow |
| BID | = | twice daily |
| FEV1 | = | forced expiratory volume in one second |
| FSC | = | fluticasone propionate/salmeterol |
| FP | = | fluticasone propionate |
| ICS | = | inhaled corticosteroids |
| ITT | = | intent-to-treat |
| MON | = | montelukast |
| PFT | = | pulmonary function testing |
| PM PEF | = | evening peak expiratory flow |
| QD | = | daily |
| SAL | = | salmeterol |
| Abbreviations | ||
| AM PEF | = | morning peak expiratory flow |
| BID | = | twice daily |
| FEV1 | = | forced expiratory volume in one second |
| FSC | = | fluticasone propionate/salmeterol |
| FP | = | fluticasone propionate |
| ICS | = | inhaled corticosteroids |
| ITT | = | intent-to-treat |
| MON | = | montelukast |
| PFT | = | pulmonary function testing |
| PM PEF | = | evening peak expiratory flow |
| QD | = | daily |
| SAL | = | salmeterol |